antitubercular

Antitubercular agent-30 has antitubercular activity.

Antitubercular agent-9 exhibits potent activity against tuberculosis, demonstrating a minimum inhibitory concentration (MIC) range of 1.03-2.32 μM.

Antitubercular agent-41 is a antibacterial agent.

Pyrazinamide (Pyrazinecarboxamide), an antimycobacterial, is utilized therapeutically as an antitubercular agent, which is a synthetic pyrazinoic acid amide derivative.

Thiacetazone (Diazam) is a thiosemicarbazone that thioacetazone treatment of pulmonary tuberculosis

TBA-7371 (DprE1-IN-1) is a potent inhibitor of DprE1 and PDE6.

Antitubercular agent-33 is an effective MmpL3 inhibitor (MIC = 0.5 μM). It disrupts M. tuberculosis cell wall integrity by blocking mycolic acid transport, used for anti-TB drug development.

Antitubercular agent-47 (compound 5C) exhibits potent activity against tuberculosis and is effective against DS/MDR/XDR clinical isolates.

Antitubercular agent-42(19) is a selective inhibitor of fatty acyl-AMP ligase (FAAL), demonstrating a MIC90 of 1.4 µg/mL against M. tuberculosis H37Rv, and possesses antitubercular activity.

Antitubercular agent-43 (compound A11) is a potent, orally active antitubercular drug. It exhibits high metabolic stability against human and murine cytochrome P450 enzymes. In an acute tuberculosis mouse model, Antitubercular agent-43 demonstrates antibacterial activity.

Antitubercular agent-44 (compound 21b) displays antitubercular activity with an H37Rv MIC of 0.06 μM and is orally active.

Antitubercula agent-45 (Compound 5g) is used as both an antifungal and antitubercular agent. It demonstrates inhibitory activity against Staphylococcus aureus, MRSA, Bacillus subtilis, Escherichia coli, and Candida albicans, with MIC values of 6.4, 10.8, 6.1, 8.4, and 8.1 μM, respectively.

Antitubercular agent-46 (4B) is a compound with antitubercular and antioxidant properties, exhibiting a minimum inhibitory concentration (MIC) of 7.81 μg/mL.

Antitubercular agent-52 (Compound 7k) is a chemical compound that acts as an antitubercular agent targeting Mycobacterium tuberculosis (Mtb). It specifically inhibits the bacterium's cytochrome bcc (cyt-bcc) electron transport chain and also affects cytochrome bd (cyt-bd). By disrupting a crucial energy metabolism pathway in Mtb, Antitubercular agent-52 impedes electron transport and ATP production, showing potential for use in tuberculosis research.

Antitubercular agent-53 (Compound 5b) acts as both an antitubercular and antibacterial agent. It exhibits antitubercular activity against Mycobacterium tuberculosis H37RV with a minimum inhibitory concentration (MIC) of 4 μg/mL.

Antitubercular agent-54 is an antitubercular compound with significant intracellular activity in macrophages (EC50 of 0.68 μM). It exhibits a minimum inhibitory concentration (MIC) of 0.31 μM against Mycobacterium tuberculosis (Mtb) H37Rv cultured with cholesterol. Antitubercular agent-54 is applicable in tuberculosis research.

Antitubercular agent-55 (Compound 2e) is an agent that combats Mycobacterium tuberculosis. It shows significant inhibitory activity against the standard H37Rv strain of Mycobacterium tuberculosis and moderate inhibitory activity against multidrug-resistant tuberculosis (MDR-TB). Antitubercular agent-55 exhibits strong affinity for the key enzyme InhA in mycolic acid biosynthesis. This compound is useful for studying Mycobacterium tuberculosis infections.

Antitubercular agent-56, a derivative of Questiomycin A, is a potent antitubercular compound effective when taken orally. By inhibiting FabD (Kd = 9.39 μM; IC50 = 49.60 μM), it compromises the cell membrane integrity of Mycobacterium tuberculosis. Antitubercular agent-56 demonstrates significant intracellular antimycobacterial activity against Mycobacterium tuberculosis (MTB) and drug-resistant MTB both in vitro and in vivo, making it valuable for tuberculosis (TB) research.

Antitubercular agent-28 (compound 2) exhibits antimycobacterial activity against resistant isolates of Mycobacterium tuberculosis H37Rv with an MIC of 4.5 μM, an IC50 of 1.5 μM, and an IC90 of 2.5 μM. It demonstrates effective intracellular antimycobacterial activity with low cytotoxicity [1].

Antitubercular agent-11 (Compound 1e) contains a bulkier electron-donating group (Bu-t) and exhibits the best MIC value of 0.060 μg/mL [1].

Antitubercular agent-15 (Compound 5n) is an antitubercular agent with low cytotoxicity against pulmonary fibroblasts and macrophages. The MIC90 values against M. tuberculosis H37Rv, CF16, CF61, CF76, CF152, and CF161 are 0.73, 7.69, 9.38, 18.80, 7.53, and 7.31 μg/mL, respectively [1].

Antitubercular agent-14 (Compound 1) exhibits antitubercular activity with an MIC value of 0.3 μg/mL against M. tuberculosis [1].

Antitubercular agent-21 (Compound 15) is an antitubercular agent with low cytotoxicity, exhibiting an MIC of 0.4 μg/mL against M. tuberculosis H37Rv. However, it shows lower activity against other microorganisms, including gram-positive bacteria, gram-negative bacteria, and fungi [1].

Antitubercular agent-27 (compound 1) exhibits potent antitubercular properties with an IC50 of 3.2 μM, an MIC of 7.8 μM, and an IC90 of 7.0 μM, effectively targeting resistant Mycobacterium tuberculosis H37Rv isolates and displaying significant intracellular antimycobacterial activity with low cytotoxicity [1].